Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 76

1.

The involvement of Kras gene 3'-UTR polymorphisms in risk of cancer and influence on patient response to anti-EGFR therapy in metastatic colorectal cancer: a meta-analysis.

Ying HQ, Wang F, He BS, Pan YQ, Gao TY, Xu YQ, Li R, Deng QW, Sun HL, Wang SK.

Onco Targets Ther. 2014 Aug 25;7:1487-96. doi: 10.2147/OTT.S65496. eCollection 2014.

2.

rs61764370 polymorphism of Kras and risk of cancer in Caucasian population: A meta-analysis.

Zhang SY, Shi J.

J Cancer Res Ther. 2016 Apr-Jun;12(2):699-704. doi: 10.4103/0973-1482.147379.

3.

Association of rs712 polymorphism in Kras gene 3'-luntranslated region and cancer risk: a meta-analysis.

Zhao WH, Qu XF, Xing ZG, Zhao LQ, Qin L, Lv C.

J BUON. 2015 Jan-Feb;20(1):309-16. Review.

PMID:
25778332
4.

rs712 polymorphism within let-7 microRNA-binding site might be involved in the initiation and progression of colorectal cancer in Chinese population.

Jiang QH, Peng HX, Zhang Y, Tian P, Xi ZL, Chen H.

Onco Targets Ther. 2015 Oct 22;8:3041-5. doi: 10.2147/OTT.S89746. eCollection 2015.

5.

FCGR2A, FCGR3A polymorphisms and therapeutic efficacy of anti-EGFR monoclonal antibody in metastatic colorectal cancer.

Ying HQ, Wang F, Chen XL, He BS, Pan YQ, Jie C, Liu X, Cao WJ, Peng HX, Lin K, Wang SK.

Oncotarget. 2015 Sep 29;6(29):28071-83. doi: 10.18632/oncotarget.4872.

6.

The LCS6 polymorphism in the binding site of let-7 microRNA to the KRAS 3'-untranslated region: its role in the efficacy of anti-EGFR-based therapy in metastatic colorectal cancer patients.

Sebio A, Paré L, Páez D, Salazar J, González A, Sala N, del Río E, Martín-Richard M, Tobeña M, Barnadas A, Baiget M.

Pharmacogenet Genomics. 2013 Mar;23(3):142-7. doi: 10.1097/FPC.0b013e32835d9b0b.

PMID:
23324806
7.

KRAS Gene Polymorphisms and their Impact on Breast Cancer Risk in an Iranian Population

Sanaei S, Hashemi M, Eskandari E, Hashemi SM, Bahari G.

Asian Pac J Cancer Prev. 2017 May 1;18(5):1301-1305.

8.

Association of a let-7 KRAS rs712 polymorphism with the risk of breast cancer.

Huang X, Yang Y, Guo Y, Cao ZL, Cui ZW, Hu TC, Gao LB.

Genet Mol Res. 2015 Dec 14;14(4):16913-20. doi: 10.4238/2015.December.14.19.

9.

Significant association between Let-7-KRAS rs712 G > T polymorphism and cancer risk in the Chinese population: a meta-analysis.

Du XY, Hu YY, Xie C, Deng CY, Liu CY, Luo ZG, Niu YM, Shen M.

Oncotarget. 2017 Feb 21;8(8):13863-13871. doi: 10.18632/oncotarget.14672.

10.

Comparison of the prevalence of KRAS-LCS6 polymorphism (rs61764370) within different tumour types (colorectal, breast, non-small cell lung cancer and brain tumours). A study of the Czech population.

Uvirova M, Simova J, Kubova B, Dvorackova N, Tomaskova H, Sedivcova M, Dite P.

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2015 Sep;159(3):466-71. doi: 10.5507/bp.2015.029. Epub 2015 Jun 11.

11.

KRAS Testing for Anti-EGFR Therapy in Advanced Colorectal Cancer: An Evidence-Based and Economic Analysis.

Health Quality Ontario.

Ont Health Technol Assess Ser. 2010;10(25):1-49. Epub 2010 Dec 1.

12.

Immunoglobulin G fragment C receptor polymorphisms and KRAS mutations: are they useful biomarkers of clinical outcome in advanced colorectal cancer treated with anti-EGFR-based therapy?

Paez D, Paré L, Espinosa I, Salazar J, del Rio E, Barnadas A, Marcuello E, Baiget M.

Cancer Sci. 2010 Sep;101(9):2048-53. doi: 10.1111/j.1349-7006.2010.01621.x.

13.

Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?

Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group.

Genet Med. 2013 Jul;15(7):517-27. doi: 10.1038/gim.2012.184. Epub 2013 Feb 21.

PMID:
23429431
14.

KRAS polymorphisms are associated with survival of CRC in Chinese population.

Dai Q, Wei HL, Huang J, Zhou TJ, Chai L, Yang ZH.

Tumour Biol. 2016 Apr;37(4):4727-34. doi: 10.1007/s13277-015-4314-1. Epub 2015 Oct 29.

PMID:
26515332
15.

Anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer: a meta-analysis.

Song QB, Wang Q, Hu WG.

World J Gastroenterol. 2015 Apr 14;21(14):4365-72. doi: 10.3748/wjg.v21.i14.4365. Review.

16.
17.

KRAS status and resistance to epidermal growth factor receptor tyrosine-kinase inhibitor treatment in patients with metastatic colorectal cancer: a meta-analysis.

Li W, Shi Q, Wang W, Liu J, Ren J, Li Q, Hou F.

Colorectal Dis. 2014 Nov;16(11):O370-8. doi: 10.1111/codi.12749. Review.

PMID:
25155261
18.
19.

Fc gamma receptor IIIa polymorphisms in advanced colorectal cancer patients correlated with response to anti-EGFR antibodies and clinical outcome.

Calemma R, Ottaiano A, Trotta AM, Nasti G, Romano C, Napolitano M, Galati D, Borrelli P, Zanotta S, Cassata A, Castello G, Iaffaioli VR, Scala S.

J Transl Med. 2012 Nov 21;10:232. doi: 10.1186/1479-5876-10-232.

20.

Association between the KRAS Gene Polymorphisms and Papillary Thyroid Carcinoma in a Chinese Han Population.

Ning L, Rao W, Yu Y, Liu X, Pan Y, Ma Y, Liu R, Zhang S, Sun H, Yu Q.

J Cancer. 2016 Dec 9;7(15):2420-2426. eCollection 2016.

Supplemental Content

Support Center